Skip to search formSkip to main contentSkip to account menu

hiltonol

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

poly ICLC

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
302 A phase IB study of indirect immunization with Oregovomab and TLR3 stimulation with hiltonol® (H) in patients with recurrent platinum resistant ovarian cancer (PROC)
Objectives This phase IB study assessed safety of Oregovomab (O) indirect immunization (monoclonal antibody for CA125) and TLR3… 
2017
2017
A phase 1b study of safety and immune response to PVX-410 vaccine alone and in combination with durvalumab (MEDI4736) in HLA-A2+ patients following adjuvant therapy for stage 2/3 triple negative…
TPS1126Background: Stage 2-3 triple negative breast cancer (TNBC) remains at high risk for recurrence despite modern adjuvant… 
2016
2016
Prophylactic and Therapeutic and Adjuvant Properties of Intranasal the Immunemodulator , Hiltonol ® ( Poly IC : LC ) , in a Lethal SARS-CoV-Infected BALB / C Mouse Model
Hiltonol®, (Poly IC: LC), a potent immunemodulator, is a synthetic, double-stranded polyriboinosinic-polyribocytidylic acid (poly… 
2016
2016
Cytosolic Receptor Melanoma Differentiation–Associated Protein 5 Mediates Preconditioning-Induced Neuroprotection Against Cerebral Ischemic Injury
Background and Purpose— Preconditioning with poly-L-lysine and carboxymethylcellulose (ICLC) provides robust neuroprotection from… 
2015
2015
Poly-ICLC as an adjuvant for NY-ESO-1 protein vaccination with or without Montanide ISA-51 VG in patients with melanoma.
e14034 Background: Poly-ICLC (Hiltonol, Oncovir Inc) is a synthetic dsRNA complex which directly activates DCs and also triggers… 
2014
2014
Phase II study with immunotherapy with dendritic cells (DC) and intratumoral hiltonol in patients with advanced solid tumors.
TPS3113 Background: DC vaccines have proved efficacy in the treatment of cancer and combination strategies are expected to… 
2014
2014
Immunostimulatory Effects of Triggering TLR3 Signaling Pathway — Implication for Cancer Immunotherapy
Immunostimulation based therapies hold promise of disease-specific interventions without the toxicity and other side effects… 
2013
2013
Clinical Adjuvant Combinations Stimulate Potent B-Cell Responses In Vitro by Activating Dermal Dendritic Cells
CD14+ dermal DCs (CD14+ DDCs) have a natural capacity to activate naïve B-cells. Targeting CD14+ DDCs is therefore a rational… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)